Litcius/Paper detail

Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study

Joaquim Bellmunt, Pablo Maroto, Teresa Bonfill, Federico Vazquez, José Luis Perez‐Gracia, Nuria Juanpere, Anna Hernandez-Prat, Silvia Hernández‐Llodrà, Ana Rovira, Oscar Juan, Alejo Rodriguez-Vida

2024Clinical Genitourinary Cancer10 citationsDOI

Topics & Concepts

MedicinePaclitaxelUrothelial cancerMetastatic Urothelial CarcinomaUrothelial carcinomaOpen labelOncologyInternal medicineChemotherapyCancerAdverse effectBladder cancerPI3K/AKT/mTOR signaling in cancerBladder and Urothelial Cancer TreatmentsRenal cell carcinoma treatment
Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study | Litcius